Penserra Capital Management LLC Chemo Centryx, Inc. Transaction History

Penserra Capital Management LLC

$4.61 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2021 Feb 15, 2022	SELL	$18.38 - $40.5 $29,408 - $64,800	-1,600 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$13.18 - $19.83 $131 - $198	10 Added 0.63%	1,600 $27,000
Q2 2021 Aug 12, 2021	BUY	$9.59 - $50.88 $239 - $1,272	25 Added 1.6%	1,590 $21,000
Q1 2021 May 13, 2021	SELL	$49.53 - $68.4 $1,238 - $1,710	-25 Reduced 1.57%	1,565 $80,000
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $47,250 - $65,160	1,000 Added 169.49%	1,590 $98,000
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $27,346 - $36,397	590 New	590 $32,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Penserra Capital Management LLC with notifications on news.